Company: ATLN
Filing Date: 2025-07-08
Form Type: 424B3
Source: 0001213900-25-062079
Chunk: 27

Company: ATLANTIC INTERNATIONAL CORP.
Filing Date: 2025-07-08
Form: 424B3
Chunk 27
---
, export control, sanctions, and other trade laws and regulations, which are collectively
referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants,
consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly,
corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws
can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments,
breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials
and employees of government agencies or government-affiliated hospitals, universities, and other organizations.

Risks Related to Ownership of Our Common Stock

The market price of our common stock may be highly volatile, and you could lose all or part of your investment.

The market price of our common
stock may be highly volatile. You may be unable to sell your shares of common stock at or above the offering price. The market prices
of our common stock could be subject to wide fluctuations in response to a variety of factors, which include:

| ● | actual or anticipated fluctuations in our financial condition and operating results; |

| ● | announcements of technological innovations by us or our competitors; |

| ● | announcements by our customers, partners or suppliers relating directly or indirectly to our products, 
 services or technologies;                                                                              |

<div align='center'>12</div>

| ● | overall conditions in our industry and market; |

| ● | addition or loss of significant customers; |

| ● | change in laws or regulations applicable to our products; |

| ● | actual or anticipated changes in our growth rate relative to our competitors; |

| ● | announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, 
 capital commitments or achievement of significant milestones;                                               |

| ● | additions or departures of key personnel; |

| ● | competition from existing products or new products that may emerge; |

| ● | fluctuations in the valuation of companies perceived by investors to be comparable to us; |

| ● | disputes or other developments related to proprietary rights, including patents, litigation matters or 
 our ability to obtain intellectual property protection for our technologies;                           |

| ● | announcement or expectation of additional financing efforts; |

| ● | sales of our common stock or warrants by us or our stockholders; |

|